Literature DB >> 20047919

Evaluation of new thiazolide/thiadiazolide derivatives reveals nitro group-independent efficacy against in vitro development of Cryptosporidium parvum.

Gilles Gargala1, Laetitia Le Goff, Jean-Jacques Ballet, Loic Favennec, Andrew V Stachulski, Jean-François Rossignol.   

Abstract

Thirty-nine new thiazolide/thiadiazolide compounds were compared with the nitrothiazole nitazoxanide for activity against Cryptosporidium parvum development in HCT-8 cells. Twenty-seven agents exerted > or =90% inhibition. Agents with a lower 50% inhibitory concentration (IC(50)) than nitazoxanide were either NO(2) or halogen 5 substituted on the thiazole moiety. Other 5 substitutions such as methyl, C(3)H(7), C(6)H(11), H, SO(2)CH(3), and SCH(3) negatively impacted activity. Five-substituted deacetylated analogues exhibited higher IC(50)s than their acetylated counterparts. Halogeno-thiazolide/thiadiazolides may provide valuable nitro-free alternatives to nitazoxanide.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20047919      PMCID: PMC2825981          DOI: 10.1128/AAC.00614-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

Review 1.  Cryptosporidiosis.

Authors:  Xian-Ming Chen; Janet S Keithly; Carlos V Paya; Nicholas F LaRusso
Journal:  N Engl J Med       Date:  2002-05-30       Impact factor: 91.245

Review 2.  Recent advances in the search for new anti-coccidial drugs.

Authors:  G H Coombs; S Müller
Journal:  Int J Parasitol       Date:  2002-05       Impact factor: 3.981

3.  Inhibitory activities of epidermal growth factor receptor tyrosine kinase-targeted dihydroxyisoflavone and trihydroxydeoxybenzoin derivatives on Sarcocystis neurona, Neospora caninum, and Cryptosporidium parvum development.

Authors:  G Gargala; A Baishanbo; L Favennec; A François; J J Ballet; J-F Rossignol
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

4.  Nitazoxanide: a new thiazolide antiparasitic agent.

Authors:  LeAnne M Fox; Louis D Saravolatz
Journal:  Clin Infect Dis       Date:  2005-03-14       Impact factor: 9.079

5.  Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of Nitazoxanide.

Authors:  J F Rossignol; A Ayoub; M S Ayers
Journal:  J Infect Dis       Date:  2001-05-29       Impact factor: 5.226

6.  Enzyme immunoassay detection of Cryptosporidium parvum inhibition by sinefungin in sporozoite infected HCT-8 enterocytic cells.

Authors:  G Gargala; A Delaunay; L Favennec; P Brasseur; J J Ballet
Journal:  Int J Parasitol       Date:  1999-05       Impact factor: 3.981

7.  Efficacy of nitazoxanide, tizoxanide and tizoxanide glucuronide against Cryptosporidium parvum development in sporozoite-infected HCT-8 enterocytic cells.

Authors:  G Gargala; A Delaunay; X Li; P Brasseur; L Favennec; J J Ballet
Journal:  J Antimicrob Chemother       Date:  2000-07       Impact factor: 5.790

8.  In vitro efficacies of nitazoxanide and other thiazolides against Neospora caninum tachyzoites reveal antiparasitic activity independent of the nitro group.

Authors:  Marco Esposito; Rebecca Stettler; Shelley L Moores; Chandrakala Pidathala; Norbert Müller; Andrew Stachulski; Neil G Berry; Jean-Francois Rossignol; Andrew Hemphill
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

9.  Efficacy of nitazoxanide against Cryptosporidium parvum in cell culture and in animal models.

Authors:  C M Theodos; J K Griffiths; J D'Onfro; A Fairfield; S Tzipori
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

10.  Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level.

Authors:  Jean François Rossignol; Simone La Frazia; Lucia Chiappa; Alessandra Ciucci; M Gabriella Santoro
Journal:  J Biol Chem       Date:  2009-07-28       Impact factor: 5.157

View more
  8 in total

Review 1.  Understanding drug resistance in human intestinal protozoa.

Authors:  Hend Aly El-Taweel
Journal:  Parasitol Res       Date:  2015-03-19       Impact factor: 2.289

Review 2.  Antiparasitic therapy.

Authors:  Shanthi Kappagoda; Upinder Singh; Brian G Blackburn
Journal:  Mayo Clin Proc       Date:  2011-06       Impact factor: 7.616

3.  Thiazolides as novel antiviral agents. 1. Inhibition of hepatitis B virus replication.

Authors:  Andrew V Stachulski; Chandrakala Pidathala; Eleanor C Row; Raman Sharma; Neil G Berry; Mazhar Iqbal; Joanne Bentley; Sarah A Allman; Geoffrey Edwards; Alison Helm; Jennifer Hellier; Brent E Korba; J Edward Semple; Jean-Francois Rossignol
Journal:  J Med Chem       Date:  2011-05-23       Impact factor: 7.446

Review 4.  An Overview of Mucosa-Associated Protozoa: Challenges in Chemotherapy and Future Perspectives.

Authors:  Helena Lucia Carneiro Santos; Karina M Rebello
Journal:  Front Cell Infect Microbiol       Date:  2022-04-25       Impact factor: 6.073

Review 5.  Burden of disease from cryptosporidiosis.

Authors:  Debbie-Ann T Shirley; Shannon N Moonah; Karen L Kotloff
Journal:  Curr Opin Infect Dis       Date:  2012-10       Impact factor: 4.915

6.  Activity of halogeno-thiazolides against Cryptosporidium parvum in experimentally infected immunosuppressed gerbils (Meriones unguiculatus).

Authors:  Gilles Gargala; Arnaud François; Loïc Favennec; Jean-François Rossignol
Journal:  Antimicrob Agents Chemother       Date:  2013-03-11       Impact factor: 5.191

7.  N-(5-Nitro-1,3-thia-zol-2-yl)-4-(tri-fluoro-meth-yl)benzamide.

Authors:  Xi-Wang Liu; Han Zhang; Ya-Jun Yang; Jian-Yong Li; Ji-Yu Zhang
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2013-05-22

Review 8.  Nitazoxanide: a first-in-class broad-spectrum antiviral agent.

Authors:  Jean-François Rossignol
Journal:  Antiviral Res       Date:  2014-08-07       Impact factor: 5.970

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.